LY317615
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Hodgkin's Lymphoma
Conditions
Non-Hodgkin's Lymphoma
Trial Timeline
Jun 1, 2002 → Sep 1, 2008
NCT ID
NCT00042666About LY317615
LY317615 is a phase 2 stage product being developed by Eli Lilly for Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00042666. Target conditions include Non-Hodgkin's Lymphoma.
What happened to similar drugs?
7 of 20 similar drugs in Non-Hodgkin's Lymphoma were approved
Approved (7) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00042666 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Hodgkin's Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 35 |
| Tazemetostat | Eisai | Phase 2 | 35 |
| ONTAK | Eisai | Phase 2 | 35 |
| Tazemetostat | Eisai | Phase 1 | 29 |
| ME-401 | Kyowa Kirin | Phase 1 | 29 |
| ME-401 | Kyowa Kirin | Phase 2 | 39 |
| gemcitabine | Eli Lilly | Phase 2 | 27 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 35 |
| LY4584180 + Rituximab | Eli Lilly | Phase 1 | 36 |
| Bortezomib + Rituximab + Rituximab | Johnson & Johnson | Phase 3 | 40 |
| HRS-3738 | Jiangsu Hengrui Medicine | Phase 1 | 25 |
| SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| ABT-199 + Ketoconazole | AbbVie | Phase 1 | 29 |
| ABT-199 + Rifampin | AbbVie | Phase 1 | 21 |
| [14C]ABT-199 (GDC-0199) | AbbVie | Phase 1 | 21 |
| ABT-199 + Rituximab + Bendamustine | AbbVie | Phase 1 | 29 |
| ABBV-291 | AbbVie | Phase 1 | 36 |
| ABT-199 | AbbVie | Phase 1 | 29 |
| Avelumab | Merck | Phase 1 | 33 |
| Pembrolizumab + Flt3L + Poly ICLC | Merck | Phase 1/2 | 28 |